PRODUCTS & SERVICES
CUSTOM OLIGO SYNTHESISRNA SEQUENCINGFLUORESCENT IN SITU HYBRIDIZATIONPERSONALIZED DIAGNOSTICS
MultiplexDX, an absolute winner of Startup Awards Slovakia 2016, released a new company video about its innovative biotech technology for personalized and 100% accurate cancer diagnostics. As of today, cancer is known to have many genomic alterations and mutations. Sadly, all its patients are still treated the same – caught up in a vicious circle of diagnoses, treatments and monitoring (that turn into relapses, re-diagnoses, modified treatments and repeated monitoring). Because of this let’s-see-what-happens approach, almost 50% of diagnosed patients lose their fight!
“Our goal at MultiplexDX is to significantly increase the number of cancer survivors with personalized, 100% accurate, life-saving diagnostic technologies. We combine visualization and sequencing methods to make a specific “barcode” for each cancer. This is then used to determine a personalized treatment program, enabling an oncologist to make an evidence-based decision and target treatment quickly, directly and more accurately. Each of us is special. And so should be the way we are treated.”
comments Dr. Vladimir Wolf, Founder and CBO of MultiplexDX.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.